Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease

References

1. 1.↵
   2. Ross CA,
   3. Aylward EH,
   4. Wild EJ, et al

   . Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204–16 doi:10.1038/nrneurol.2014.24 pmid:24614516

   CrossRefPubMed
2. 2.↵
   A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes: the Huntington's Disease Collaborative Research Group. Cell 1993;72:971–83 doi:10.1016/0092-8674(93)90585-E pmid:8458085

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Gusella JF,
   3. Wexler NS,
   4. Conneally PM, et al

   . A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234–38 doi:10.1038/306234a0 pmid:6316146

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Tabrizi SJ,
   3. Scahill RI,
   4. Durr A, et al

   ; TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31–42 doi:10.1016/S1474-4422(10)70276-3 pmid:21130037

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Paulsen JS,
   3. Nopoulos PC,
   4. Aylward E, et al

   ; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG). Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010;82:201–07 doi:10.1016/j.brainresbull.2010.04.003 pmid:20385209

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Ross CA,
   3. Tabrizi SJ

   . Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83–98 doi:10.1016/S1474-4422(10)70245-3 pmid:21163446

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Tabrizi SJ,
   3. Langbehn DR,
   4. Leavitt BR, et al

   ; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801 doi:10.1016/S1474-4422(09)70170-X pmid:19646924

   CrossRefPubMedWeb of Science
8. 8.↵
   2. van den Bogaard SJ,
   3. Dumas EM,
   4. Acharya TP, et al

   ; TRACK-HD Investigator Group. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 2011;258:412–20 doi:10.1007/s00415-010-5768-0 pmid:20936300

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Aylward EH,
   3. Li Q,
   4. Stine OC, et al

   . Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394–99 doi:10.1212/WNL.48.2.394 pmid:9040728

   Abstract/FREE Full Text
10. 10.↵
    2. Browne SE,
    3. Beal MF

    . Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8:2061–73 doi:10.1089/ars.2006.8.2061 pmid:17034350

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Muller M,
    3. Leavitt BR

    . Iron dysregulation in Huntington's disease. J Neurochem 2014;130:328–50 doi:10.1111/jnc.12739 pmid:24717009

    CrossRefPubMed
12. 12.↵
    2. Douaud G,
    3. Behrens TE,
    4. Poupon C, et al

    . In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 2009;46:958–66 doi:10.1016/j.neuroimage.2009.03.044 pmid:19332141

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Dominguez DJ,
    3. Ng AC,
    4. Poudel G, et al

    . Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study. J Neurol Neurosurg Psychiatry 2015 May 7. [Epub ahead of print] doi:10.1136/jnnp-2014-310183 pmid:25952334

    CrossRefPubMed
14. 14.↵
    2. Vonsattel JP

    . Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008;115:55–69 pmid:17978822

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Chen J,
    3. Marks E,
    4. Lai B, et al

    . Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One 2013;8:e77023 doi:10.1371/journal.pone.0077023 pmid:24146952

    CrossRefPubMed
16. 16.↵
    2. Chen JC,
    3. Hardy PA,
    4. Kucharczyk W, et al

    . MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 1993;14:275–81 pmid:8456699

    Abstract/FREE Full Text
17. 17.↵
    2. Rosas HD,
    3. Chen YI,
    4. Doros G, et al

    . Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 2012;69:887–93 pmid:22393169

    CrossRefPubMed
18. 18.↵
    2. Sánchez-Castañeda C,
    3. Squitieri F,
    4. Di Paola M, et al

    . The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study. Hum Brain Mapp 2015;36:50–66 doi:10.1002/hbm.22612 pmid:25145324

    CrossRefPubMed
19. 19.↵
    2. Sánchez-Castañeda C,
    3. Cherubini A,
    4. Elifani F, et al

    . Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 2013;34:1625–35 doi:10.1002/hbm.22019 pmid:22359398

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Apple AC,
    3. Possin KL,
    4. Satris G, et al

    . Quantitative 7T phase imaging in premanifest Huntington disease. AJNR Am J Neuroradiol 2014;35:1707–13 doi:10.3174/ajnr.A3932 pmid:24742810

    Abstract/FREE Full Text
21. 21.↵
    2. Dumas EM,
    3. Versluis MJ,
    4. van den Bogaard SJ, et al

    ; TRACK-HD investigators. Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 2012;61:558–64 doi:10.1016/j.neuroimage.2012.03.056 pmid:22480728

    CrossRefPubMed
22. 22.↵
    2. Salomir R,
    3. De Senneville BD,
    4. Moonen CT

    . A fast calculation method for magnetic field inhomogeneity due to an arbitrary distribution of bulk susceptibility. Concept Magn Reson B 2003:19B:26–34 doi:10.1002/cmr.b.10083

    CrossRef
23. 23.↵
    2. Deistung A,
    3. Schäfer A,
    4. Schweser F, et al

    . Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. Neuroimage 2013;65:299–314 doi:10.1016/j.neuroimage.2012.09.055 pmid:23036448

    CrossRefPubMed
24. 24.↵
    2. Lim IA,
    3. Faria AV,
    4. Li X, et al

    . Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures. Neuroimage 2013;82:449–69 doi:10.1016/j.neuroimage.2013.05.127 pmid:23769915

    CrossRefPubMed
25. 25.↵
    2. Schweser F,
    3. Sommer K,
    4. Deistung A, et al

    . Quantitative susceptibility mapping for investigating subtle susceptibility variations in the human brain. Neuroimage 2012;62:2083–100 doi:10.1016/j.neuroimage.2012.05.067 pmid:22659482

    CrossRefPubMed
26. 26.↵
    2. Wharton S,
    3. Schäfer A,
    4. Bowtell R

    . Susceptibility mapping in the human brain using threshold-based k-space division. Magn Reson Med 2010;63:1292–304 doi:10.1002/mrm.22334 pmid:20432300

    CrossRefPubMed
27. 27.↵
    2. Li W,
    3. Wu B,
    4. Liu C

    . Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645–56 doi:10.1016/j.neuroimage.2010.11.088 pmid:21224002

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Schenck JF

    . The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Medi Phys 1996;23:815–50 doi:10.1118/1.597854 pmid:8798169

    CrossRefPubMed
29. 29.↵
    2. Schweser F,
    3. Deistung A,
    4. Lehr BW, et al

    . Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? Neuroimage 2011;54:2789–807 doi:10.1016/j.neuroimage.2010.10.070 pmid:21040794

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Langkammer C,
    3. Schweser F,
    4. Krebs N, et al

    . Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012;62:1593–99 doi:10.1016/j.neuroimage.2012.05.049 pmid:22634862

    CrossRefPubMed
31. 31.↵
    2. Poynton CB,
    3. Lupo JM,
    4. Hess C, et al

    . Quantitative susceptibility mapping of Huntington's disease at 7 Tesla. In: Proceedings of the Joint Annual Meeting of the International Society for Magnetic Resonance in Medicine and the European Society for Magnetic Resonance in Medicine, Milan, Italy. May 10–16, 2014
32. 32.↵
    Unified Huntington's Disease Rating Scale: reliability and consistency—Huntington Study Group. Mov Disord 1996;11:136–42 doi:10.1002/mds.870110204 pmid:8684382

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Zhang Y,
    3. Long JD,
    4. Mills JA, et al

    ; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011:156B:751–63 doi:10.1002/ajmg.b.31232 pmid:21858921

    CrossRefPubMed
34. 34.↵
    2. Hamilton M

    . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62 doi:10.1136/jnnp.23.1.56 pmid:14399272

    FREE Full Text
35. 35.↵
    2. Nasreddine ZS,
    3. Phillips NA,
    4. Bedirian V, et al

    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–99 doi:10.1111/j.1532-5415.2005.53221.x pmid:15817019

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Bright P,
    3. Jaldow E,
    4. Kopelman MD

    . The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc 2002;8:847–54 doi:10.1017/S1355617702860131 pmid:12240749

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Wharton S,
    3. Bowtell R

    . Fiber orientation-dependent white matter contrast in gradient echo MRI. Proc Natl Acad Sci U S A 2012;109:18559–64 doi:10.1073/pnas.1211075109 pmid:23091011

    Abstract/FREE Full Text
38. 38.↵
    2. Wu B,
    3. Li W,
    4. Guidon A, et al

    . Whole brain susceptibility mapping using compressed sensing. Magnetic Reson Med 2012;67:137–47 doi:10.1002/mrm.23000 pmid:21671269

    CrossRefPubMed
39. 39.↵
    2. Wu B,
    3. Li W,
    4. Avram AV, et al

    . Fast and tissue-optimized mapping of magnetic susceptibility and T2* with multi-echo and multi-shot spirals. Neuroimage 2012;59:297–305 doi:10.1016/j.neuroimage.2011.07.019 pmid:21784162

    CrossRefPubMed
40. 40.↵
    2. Zhang Y,
    3. Zhang J,
    4. Hsu J, et al

    . Evaluation of group-specific, whole-brain atlas generation using Volume-based Template Estimation (VTE): application to normal and Alzheimer's populations. Neuroimage 2014;84:406–19 doi:10.1016/j.neuroimage.2013.09.011 pmid:24051356

    CrossRefPubMed
41. 41.↵
    2. Bartzokis G,
    3. Cummings J,
    4. Perlman S, et al

    . Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569–74 doi:10.1001/archneur.56.5.569 pmid:10328252

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Dexter DT,
    3. Carayon A,
    4. Javoy-Agid F, et al

    . Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953–75 doi:10.1093/brain/114.4.1953 pmid:1832073

    Abstract/FREE Full Text
43. 43.↵
    2. Langkammer C,
    3. Krebs N,
    4. Goessler W, et al

    . Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455–62 doi:10.1148/radiol.10100495 pmid:20843991

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Bartzokis G,
    3. Lu PH,
    4. Tishler TA, et al

    . Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007;32:1655–64 doi:10.1007/s11064-007-9352-7 pmid:17484051

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Langkammer C,
    3. Liu T,
    4. Khalil M, et al

    . Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–59 doi:10.1148/radiol.12120707 pmid:23315661

    CrossRefPubMedWeb of Science
46. 46.↵
    2. Harris GJ,
    3. Codori AM,
    4. Lewis RF, et al

    . Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999;122:1667–78 doi:10.1093/brain/122.9.1667 pmid:10468506

    Abstract/FREE Full Text
47. 47.↵
    2. Hasselbalch SG,
    3. Oberg G,
    4. Sorensen SA, et al

    . Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry 1992;55:1018–23 doi:10.1136/jnnp.55.11.1018 pmid:1469396

    Abstract/FREE Full Text
48. 48.↵
    2. Chen JJ,
    3. Salat DH,
    4. Rosas HD

    . Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease. Neuroimage 2012;59:1043–51 doi:10.1016/j.neuroimage.2011.08.112 pmid:21945790

    CrossRefPubMed
49. 49.↵
    2. Hua J,
    3. Unschuld PG,
    4. Margolis RL, et al

    . Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Mov Disord 2014;29:396–401 doi:10.1002/mds.25591 pmid:23847161

    CrossRefPubMed
50. 50.↵
    2. Lin C,
    3. Huang C,
    4. Lin M, et al

    . Magnetic resonance microscopic angiography visualization of abnormal microvasculature in a transgenic mouse model of Huntington's disease. In: Proceedings of the ISMRM 18th Scientific Meeting and Exhibition, Stockholm, Sweden. May 1–7, 2010